Name
ABIRATERONE ACETATE
Mode of Action
IT IS CYP17 INHIBITOR, INDICATED IN COMBINATION WITH PREDNISOLONE FOR THE TREATMENT OF METASTATIC, CASTRATION RESISTANT PROSTATE CANCER WHO HAVE RECIEVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL.
Dosage
1000 MG ONCE DAILY BEFORE MEALS IN COMBINATION WITH PREDNISOLONE 5 MG TWICE DAILY. NO FOOD SHOULD BE GIVEN 2 HRS BEFORE & ONE HR. AFTER THE MEDICINE.
Drug Group
[ANTICANCER] , [CYP17 INHIBITOR]
Cross Reaction
CO-ADMINISTRATION WITH CYP2D6 SUBSTRATES THAT HAVE NARROW THERAPEUTIC INDEX SHOULD BE AVOIDED. CONCOMITANT USE WITH DABRAFENIB, REPAGLANIDE & SELEXIPAG CAN RESULT IN DECREASED PLASMA CONCENTRATION OF THESE DRUGS.
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph